HCV genotype 4 subtypes in people who inject drugs in sub-Saharan Africa.
作者信息
Akiyama Matthew J, Nyakowa Mercy, Riback Lindsey R, Cherutich Peter, Kurth Ann E
机构信息
Department of Medicine, Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, NY 10467, USA.
National AIDS and STI Control Programme (NASCOP), Kenya Ministry of Health, Nairobi, Kenya.
出版信息
Lancet Gastroenterol Hepatol. 2022 Aug;7(8):699. doi: 10.1016/S2468-1253(22)00175-3.
Abstract
摘要
相似文献
1
HCV genotype 4 subtypes in people who inject drugs in sub-Saharan Africa.撒哈拉以南非洲地区注射毒品者中的丙型肝炎病毒4型亚型
Lancet Gastroenterol Hepatol. 2022 Aug;7(8):699. doi: 10.1016/S2468-1253(22)00175-3.
2
Is resistance to direct-acting antivirals in sub-Saharan Africa a threat to HCV elimination? Recommendations for action.撒哈拉以南非洲地区对直接作用抗病毒药物的耐药性是否会对丙型肝炎病毒的消除构成威胁？行动建议。
J Hepatol. 2020 Mar;72(3):583-584. doi: 10.1016/j.jhep.2019.10.017. Epub 2019 Dec 10.
3
Epidemiology of hepatitis C virus and genotype distribution in immigrants crossing to Europe from North and sub-Saharan Africa.丙型肝炎病毒的流行病学及从北非和撒哈拉以南非洲进入欧洲的移民中的基因型分布。
Travel Med Infect Dis. 2016 Sep-Oct;14(5):517-526. doi: 10.1016/j.tmaid.2016.05.020. Epub 2016 Aug 5.
4
Hepatitis C virus in sub-Saharan Africa: a long road to elimination.撒哈拉以南非洲的丙型肝炎病毒：通往消除的漫长道路。
Lancet Gastroenterol Hepatol. 2021 Sep;6(9):693-694. doi: 10.1016/S2468-1253(21)00224-7.
5
Prevalence, estimated incidence, risk behaviours, and genotypic distribution of hepatitis C virus among people who inject drugs accessing harm-reduction services in Kenya: a retrospective cohort study.肯尼亚注射毒品者利用减少伤害服务的丙型肝炎病毒流行率、估计发病率、风险行为和基因型分布：一项回顾性队列研究。
Lancet Infect Dis. 2019 Nov;19(11):1255-1263. doi: 10.1016/S1473-3099(19)30264-6. Epub 2019 Sep 17.
6
Hepatitis B, hepatitis C and HIV prevalence and related sexual and substance use risk practices among key populations who access HIV prevention, treatment and related services in South Africa: findings from a seven-city cross-sectional survey (2017).南非获取艾滋病毒预防、治疗和相关服务的重点人群中的乙型肝炎、丙型肝炎和艾滋病毒流行情况以及相关的性和物质使用风险行为：来自七个城市横断面调查的结果（2017 年）。
BMC Infect Dis. 2020 Sep 7;20(1):655. doi: 10.1186/s12879-020-05359-y.
7
Reply to: "Is resistance to direct-acting antivirals in sub-Saharan Africa a threat to HCV elimination? Recommendations for action".回复：“撒哈拉以南非洲地区对直接作用抗病毒药物的耐药性是否会对丙型肝炎病毒消除构成威胁？行动建议”
J Hepatol. 2020 Mar;72(3):585-586. doi: 10.1016/j.jhep.2019.11.010. Epub 2019 Dec 20.
8
Prevalence of HIV, Hepatitis B and C Infections and an Assessment of HCV-Genotypes and Two IL28B SNPs among People Who Inject Drugs in Three Regions of Nepal.尼泊尔三个地区注射吸毒者中艾滋病毒、乙型和丙型肝炎感染率以及丙型肝炎病毒基因型和两个IL28B单核苷酸多态性的评估
PLoS One. 2015 Aug 11;10(8):e0134455. doi: 10.1371/journal.pone.0134455. eCollection 2015.
9
Treatment of Hepatitis C Genotypes 1 to 5 in Sub-Saharan Africa Using Direct-Acting Antivirals.撒哈拉以南非洲地区使用直接作用抗病毒药物治疗 1 至 5 型丙型肝炎。
Am J Trop Med Hyg. 2020 Nov;103(5):2083-2084. doi: 10.4269/ajtmh.20-0367.
10
Genotypes and subtypes of hepatitis C virus in Burundi: a particularity in sub-Saharan Africa.布隆迪丙型肝炎病毒的基因型和亚型：撒哈拉以南非洲的一个特殊情况。
Pan Afr Med J. 2014 Sep 24;19:69. doi: 10.11604/pamj.2014.19.69.4580. eCollection 2014.
引用本文的文献
1
Predictors of hepatitis C cure among people who inject drugs treated with directly observed therapy supported by peer case managers in Kenya.肯尼亚接受同伴个案管理员支持的直接观察治疗的注射吸毒者中丙型肝炎治愈的预测因素。
Int J Drug Policy. 2023 Mar;113:103959. doi: 10.1016/j.drugpo.2023.103959. Epub 2023 Feb 7.
本文引用的文献
1
Hepatitis C treatment outcomes among people who inject drugs accessing harm reduction settings in Kenya.肯尼亚注射吸毒者在减少伤害环境中接受治疗的丙型肝炎治疗结果。
J Viral Hepat. 2022 Aug;29(8):691-694. doi: 10.1111/jvh.13662. Epub 2022 Mar 15.
2
Safety and efficacy of sofosbuvir-velpatasvir to treat chronic hepatitis C virus infection in treatment-naive patients in Rwanda (SHARED-3): a single-arm trial.索磷布韦-维帕他韦治疗卢旺达初治慢性丙型肝炎病毒感染患者的安全性和有效性（SHARED-3）：一项单臂试验。
Lancet Gastroenterol Hepatol. 2022 Jun;7(6):533-541. doi: 10.1016/S2468-1253(21)00398-8. Epub 2022 Mar 3.
3
Treatment of chronic hepatitis C virus infection in Rwanda with ledipasvir-sofosbuvir (SHARED): a single-arm trial.卢旺达采用 ledipasvir-索非布韦（SHARED）治疗慢性丙型肝炎病毒感染：一项单臂试验。
Lancet Gastroenterol Hepatol. 2019 Feb;4(2):119-126. doi: 10.1016/S2468-1253(18)30382-0. Epub 2018 Dec 11.
4
Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review.全球注射吸毒流行状况以及注射吸毒者的社会人口学特征和艾滋病毒、乙肝病毒及丙肝病毒流行状况：多阶段系统评价。
Lancet Glob Health. 2017 Dec;5(12):e1192-e1207. doi: 10.1016/S2214-109X(17)30375-3. Epub 2017 Oct 23.
5
Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study.2015 年全球丙型肝炎病毒感染的流行率和基因型分布：一项建模研究。
Lancet Gastroenterol Hepatol. 2017 Mar;2(3):161-176. doi: 10.1016/S2468-1253(16)30181-9. Epub 2016 Dec 16.
Zotero 插件